ITCI Intra-Cellular Therapies Inc.

13.67
-0.42  -3%
Previous Close 14.09
Open 14.31
Price To Book 2.61
Market Cap 753,690,324
Shares 55,134,625
Volume 74,004
Short Ratio
Av. Daily Volume 372,660

NewsSee all news

  1. Before You Buy Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), Consider Its Volatility
  2. Implied Volatility Surging for Intra-Cellular (ITCI) Stock Options
  3. Intra-Cellular Therapies Announces FDA Advisory Committee Meeting to Review the NDA for Lumateperone for the Treatment of Schizophrenia in Adults
  4. Intra-Cellular Therapies to Present at Jefferies 2019 Global Healthcare Conference
  5. 2 Biotech Names See Directors Direct Cash to Their Shares

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 top-line data due 2Q 2019.
ITI-007 - Monotherapy (Study 401)
Bipolar depression
Phase 3 interim analysis December 18, 2018 noted trial to stop due to futility.
ITI-007-201
Agitation in patients with dementia
PDUFA date September 27, 2019. Advisory Committee Meeting July 31, 2019.
Lumateperone
Schizophrenia
Phase 3 enrollment to be completed 2H 2019.
ITI-007 - Adjunctive Therapy
Bipolar depression
Phase 3 top-line data due 2Q 2019.
ITI-007 - Monotherapy (Study 404)
Bipolar depression
Phase 1/2 top-line presented October 22, 2018.
ITI-214
Parkinson's disease (PD)

Latest News

  1. Before You Buy Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), Consider Its Volatility
  2. Implied Volatility Surging for Intra-Cellular (ITCI) Stock Options
  3. Intra-Cellular Therapies Announces FDA Advisory Committee Meeting to Review the NDA for Lumateperone for the Treatment of Schizophrenia in Adults
  4. Intra-Cellular Therapies to Present at Jefferies 2019 Global Healthcare Conference
  5. 2 Biotech Names See Directors Direct Cash to Their Shares
  6. Edited Transcript of ITCI earnings conference call or presentation 8-May-19 12:30pm GMT
  7. Intra-Cellular Therapies to Present at 2019 RBC Capital Markets Global Healthcare Conference
  8. Intra-Cellular Therapies Announces Presentations on Lumateperone Schizophrenia Program at the American Psychiatric Association (APA) Annual Meeting
  9. Such Is Life: How Intra-Cellular Therapies (NASDAQ:ITCI) Shareholders Saw Their Shares Drop 57%
  10. Here’s What Hedge Funds Think About Intra-Cellular Therapies Inc (ITCI)
  11. Intra-Cellular Therapies, Inc. (ITCI) Q1 2019 Earnings Call Transcript
  12. Intra-Cellular: 1Q Earnings Snapshot
  13. Intra-Cellular Therapies Reports First Quarter 2019 Financial Results and Provides Corporate Update
  14. Intra-Cellular Therapies to Host First Quarter 2019 Financial Results Conference Call and Webcast
  15. Are Options Traders Betting on a Big Move in Intra-Cellular Therapies (ITCI) Stock?
  16. Intra-Cellular Therapies Mourns the Passing of Co-Founder and Nobel Laureate, Dr. Paul Greengard
  17. Intra-Cellular Therapies Presents Additional Results From Long-term Open Label Safety Study of Lumateperone at the 2019 Congress of the Schizophrenia International Research Society
  18. Investors Who Bought Intra-Cellular Therapies (NASDAQ:ITCI) Shares Three Years Ago Are Now Down 61%
  19. Intra-Cellular Therapies Continues to Strengthen Its Commercial Leadership Team; John A. Bardi Appointed as Senior Vice President, Market Access, Policy and Government Affairs
  20. Intra-Cellular Therapies to Present at The Cowen and Company 39th Annual Health Care Conference